# First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer

> **NCT04077021** · PHASE1 · TERMINATED · sponsor: **Calibr, a division of Scripps Research** · enrollment: 22 (actual)

## Conditions studied

- Metastatic Castration-Resistant Prostate Adenocarcinoma

## Interventions

- **DRUG:** CCW702

## Key facts

- **NCT ID:** NCT04077021
- **Lead sponsor:** Calibr, a division of Scripps Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-17
- **Primary completion:** 2022-10-21
- **Final completion:** 2022-10-21
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2023-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04077021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04077021, "First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT04077021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*